Objective: Various types of conduits are available for right ventricular outflow tract (RVOT) reconstruction. We have developed an expanded polytetrafluoroethylene (ePTFE) conduit with bulging sinuses and a fan-shaped ePTFE valve. This study summarized the results of a multicenter study evaluating the valved ePTFE conduit.
The long-term outcomes of the ePTFE conduit with a fan-shaped valve and bulging sinuses appear clinically satisfactory. This ePTFE valved conduit can be one of the best ways to reconstruct the RVOT.
Perspective
A fan-shaped valve design with bulging sinuses on expanded polytetrafluoroethylene conduits has beneficial effects on long-term valve function. These valves can accomplish excellent long-term outcomes and represent a promising material for right ventricular outflow reconstruction.
See Editorial Commentary page 2577.
A large spectrum of congenital heart diseases requires valved conduits to establish anatomic continuity between the right ventricular outflow tract (RVOT) and the pulmonary artery. These valves require good performance to maintain good valve function over the long term, especially for younger children. Thus, we focused on the properties of expanded polytetrafluoroethylene (ePTFE); it has good biocompatibility, and its microporous structure impedes cellular penetration and subsequent calcification, which is a common cause of valvular dysfunction.
We have developed handmade ePTFE valves with bulging sinuses and fan-shaped valves, and we previously reported midterm results showing excellent valvular function. [1] [2] [3] [4] In Japan, these valves have been used at 65 institutes given the unavailability of homograft and bovine jugular veins, and they have shown excellent results. All the conduits that were implanted in this study were made at Kyoto Prefectural University of Medicine. Each institute asked us to make the conduits before the operations. We formed bulging sinuses on the conduit automatically using a special machine, and one author personally sutured all the fanshaped valves on all the conduits in the operating room. 2, 3 In addition, all the finished valves were sterilized and delivered to the Japanese institutes as needed. The purpose of this study was to review the clinical outcomes of the ePTFE valved conduit for RVOT reconstruction in a multicenter study (Video 1).
MATERIALS AND METHODS
This study was approved by the Institutional Review Board at Kyoto Prefectural University of Medicine (RBMR-C-657-1, January 15, 2010).
Data Collection and Statistical Analysis
This multicenter study included follow-up with each patient at the respective institutes. Preoperative and postoperative data were collected retrospectively from the patients' medical records at each institute. The conduit diameters at the time of insertion were converted into Z-values by regression analysis based on previously published nomograms, 5, 6 and a predicted pulmonary valve size was determined using a historically validated nomogram 7 indexed to the body surface area. To assess the presence of pulmonary regurgitation and to determine the mean blood pressure gradients across the valve, all patients periodically underwent transthoracic, 2-dimensional, color flow, M-mode Doppler echocardiography during follow-up at each institute. The grade of the conduit stenosis was determined using continuous Doppler to measure the maximum velocities across the conduit and the pressure gradient across the RVOT. The grades were as follows: mild, peak velocity < 3 m/s, and peak gradient<36 mm Hg; moderate, peak velocity 3 to 4 m/s, and peak gradient 36 to 64 mm Hg; and severe, peak velocity > 4 m/s, and peak gradient > 64 mm Hg. The degree of pulmonary regurgitation was classified based on a 5-grade semiquantitative scale (0, none; 1, trivial; 2, mild; 3, moderate; or 4, severe) according to the features of the jet flow as measured with pulsed Doppler echocardiography. All the criteria used for grading were based on the commonly used guidelines for echocardiograms. 8 All data are expressed as means AE standard deviation, median, and interquartile range (IQR). The Kaplan-Meier product limit method was used to analyze patient survival and freedom from reoperation.
RESULTS

Patients
Between February 2001 and January 2015, 902 patients underwent RVOT reconstruction using fan-shaped ePTFE valves and ePTFE valved conduits with bulging sinuses in 65 Japanese institutes. The inclusion criterion was the use of operative treatment as the primary correction for underlying heart disease; patients undergoing palliative procedures were excluded. The anatomic diagnoses are listed in Table 1 .
The median age at the time of operation was 3.9 years (range, 0 days to 56.8 years). There were 292 patients (32.4%) younger than 2 years. Their median body weight at the time of surgery was 12.6 kg (2.1-91.3 kg). Three hundred sixty-four patients (40.3%) had previous RVOT reconstruction with prosthetic valves. The diameters of the conduits were 8 mm in 3 patients, 10 mm in 24 patients, 12 mm in 78 patients, 14 mm in 99 patients, 16 mm in 196 patients, 18 mm in 187 patients, 20 mm in 71 patients, 22 mm in 175 patients, and 24 mm in 69 patients. Conduits smaller than 16 mm were implanted in 400 patients (44.3%). Figure 1 , A, shows the patients' body weight and the diameters of the conduits used, and Figure 1 Table 2 . The Z-value at implantation was 1.8 AE 0.8 (median, 1.9; IQR, 1.4-2.3) in patients younger than 2 years and 0.9 AE 1.0 (median, 0.8; IQR, 0-1.7) for patients older than 2 years.
At the initial construction of the bulging sinuses, the ePTFE graft needs to be formally opened, because the bulging sinuses are formed from flat molds. After the bulging sinus has been formed and the fan-shaped valve anastomosed, the graft is rolled up and sutured to form a conduit (Figure 2 , A).
2 Starting in 2010, it was no longer necessary to cut open the ePTFE because of improved fabrication techniques (Figure 2 , B). 
Mortality
The early mortality rate within 30 days after conduit implantation was 1.7% (n ¼ 15), with 8 patients dying of heart failure, 3 patients dying of respiratory failure, 2 patients dying of infection, 1 patient dying of pulmonary hypertension crisis, and 1 patient dying of other causes. The late mortality rate beyond 30 days after conduit implantation was 2.4% (n ¼ 22), with 3 patients dying of heart failure, 2 patients dying of respiratory failure, 8 patients dying of infection, 3 patients dying of sudden death, and 6 patients dying of unknown causes; however, these were not related to the valves. The overall survival rate was 96.1% at 5 years, 95.3% at 10 years, and 95.3% at 15 years ( Figure 3 ).
Conduit Replacement
Fifty-five patients (6.1%) required explantation of the conduits. The cause of explantation of the conduits was somatic growth in 12 patients, peripheral pulmonary stenosis (PS) in 10 patients, and valvular PS in 10 patients, with a concomitant procedure in 8 patients, infection in 7 patients (with conduit infection in 3 patients and infections involving other parts, such as the tricuspid valve, ventricular septal defect patch, central venous catheter, and RVOT, in 4 patients), RVOT stenosis in 3 patients, suspicion of coronary artery compression in 1 patient, and unknown cause in 2 patients. Freedom from conduit replacement was 96.3% at 5 years, 87.4% at 10 years, and 84.2% at 15 years (Figure 4, A) . Examining freedom from conduit replacement by conduit diameter, the rates for 8-to 16-mm-diameter conduits were 92.3% at 5 years, 76.1% at 10 years, and 71.9% at 12 years; for 18-to 24-mm-diameter conduits, the rates were 99.6% at 5 years, 95.1% at 10 years, and 92.6% at 15 years (Figure 4, B) . In addition, examining freedom from conduit replacement by patient age at the time of conduit implantation, the rates for those younger than 2 years were 90.0% at 5 years, 73.7% at 10 years, and 67.0% at 12 years; for those 2 years old or older, the rates 99.2% at 5 years, 92.8% at 10 years, and 90.9% at 15 years (Figure 3, C) . There were no valves placed in these conduits using a catheter-based approach.
Percutaneous Transluminal Angioplasty for Pulmonary Stenosis
Fifty-three patients (5.9%) required a catheter intervention, including 37 balloon dilatations for pulmonary artery bifurcation stenosis, 8 for valvular stenosis, and 9 for peripheral pulmonary artery stenosis.
Conduit Function
Conduit function was evaluated at the latest follow-up at a median time of 4.8 years. The degree of pulmonary regurgitation was none in 213 patients (24.0%), trivial in 331 patients (37.3%), mild in 304 patients (34.3%), moderate in 38 patients (4.3%), and severe in only 1 patient (0.1%) during the follow-up period ( Figure 5 , A).
The mean peak pressure gradient between the pulmonary artery and right ventricle was 16.5 AE 13.1 mm Hg (median, 13.0; IQR, 7-21; range, 0-72.9 mm Hg). Conduit stenosis was graded as being mild or less in 808 patients (91.1%), moderate in 64 patients (7.2%), and severe in 15 patients (1.7%) during the follow-up period ( Figure 5, B) .
The right ventricular end-diastolic volume index (RVEDVI) was measured in 308 patients, and it was more than 150 mL/m 2 in 8 patients (2.6%) and more than 170 mL/m 2 in 3 patients (1.0%).
Histologic Examination
Ten conduits removed for conduit exchange were examined histologically. Some of them showed a small amount of lymphohistiocytic inflammation that multifocally covered the surfaces of the conduit and leaflet. The interstices of the leaflet, conduit, and suture associated with the leaflet attachment region were mildly and multifocally mineralized, and the microscopic image showed that the areas of leaflet mineralization disrupted the ePTFE membrane ( Figure 6 ).
DISCUSSION
A range of materials including homografts, bovine jugular veins (Contegra; Medtronic, Minneapolis, Minn), autologous pericardium, Hancock porcine pulmonary valves (Medtronic), Dacron grafts, and mechanical valves have been used for RVOT reconstruction. Homografts and bovine jugular veins are commonly used, but early degeneration and calcification are inevitable complications. 9 Unfortunately, their long-term availability and durability are unsatisfactory. [10] [11] [12] Furthermore, Albanesi and colleagues 12 reported that the incidence of Contegra infection was 11.3% (12 of 106 patients), which is relatively high. In contrast, infection of the ePTFE conduit occurred in only 3 patients (0.3%) who required conduit replacement, a very low incidence. We use only cefazolin sodium at the time of skin incision and every 6 hours for 24 hours. In regard to longevity and resistance to infections, this ePTFE valved conduit is the best choice for RVOT reconstruction.
In engineering experiments using a pediatric right heart stimulator with a pneumatic artificial heart, the existence of bulging sinuses demonstrated a lower energy loss at the valve, a larger effective opening area, and a faster response in valve movement. Hydrodynamic experiments of various combinations of valve shapes and conduit configurations have demonstrated that the largest flow is measured in the conduit with a combination of a fan-shaped valve and a sinus of Valsalva, especially with a fan-shaped valve. In addition, the lowest pressure gradient through the valve is measured in the conduit with a combination of a fan-shaped valve and a sinus of Valsalva, especially with a bulging sinus. Energy loss is extremely low in the fanshaped valve group. Thus, good valve function can be expected to a certain extent with a fan-shaped ePTFE valve alone, and the use of a fan-shaped ePTFE valve is recommended even if the sinus cannot be constructed. However, the bulging sinus appears to be effective for the closing motion of the valve. Therefore, the combination of a fanshaped valve and a bulging sinus may contribute to valve function. 13 Invariably, patients who had a smaller conduit had a higher likelihood of needing reoperation. Vitanova and coworkers 14 reported on the durability of homografts, Contegra, and Hancock conduits that were 15 mm or less in diameter. The rates of freedom from conduit exchange at 5 years were 69.4% AE 6.6%, 59.4% AE 8.7%, and 53.8% AE 7.4% for homografts, Contegra, and Hancock conduits, respectively. The rates of freedom from conduit exchange at 10 years were 38.1% AE 8.3%, 38.0% AE 11.3%, and 20.3% AE 7.5% for homografts, Contegra, and Hancock conduits, respectively. On the other hand, for the ePTFE valved conduit with a diameter of 8 to 16 mm, the rates of freedom from conduit exchange were 92.3% at 5 years, 76.1% at 10 years, and 71.9% at 12 years; these were excellent results. In addition, for smaller-sized conduits, the optimal size was controversial; in our previous study, for smaller-sized conduits, we proposed that the first choice of a conduit for RVOT reconstruction should be an ePTFE conduit with a Z-score around 1.4. 15 Of the 27 patients with 8-to 10-mm conduits, 6 were neonates. Early death occurred in 2 patients, and late death occurred in 4 patients; 4 patients required replacement of conduits at a median time of 2.5 years (range, 1.0-5.2 years). Excellent longevity of small-sized conduits enables us to have enough time to exchange them to larger-sized conduits without loss of their valve function.
In addition, we use patches with bulging sinuses and a fan-shaped valve in the case of tetralogy of Fallot or other congenital cardiac disorders with a narrow pulmonary annulus. Conduits were chosen for patients with pulmonary atresia, truncus arteriosus, or Ross candidates who had discontinuity between the RV and the pulmonary artery. Conduits were also used in adolescents and adults who needed pulmonary valve replacements and in patients with right heart dysfunction who needed to have pulmonary regurgitation prevented completely.
Meyns and colleagues 16 reported a high incidence of severe anastomosis and site stenosis of Contegra conduits. In the present series, 37 patients (4.1%) required percutaneous transluminal angioplasty for anastomosis site stenosis, which is relatively low. However, the ePTFE conduit is harder than a homograft or bovine jugular vein, and to prevent anastomosis site stenosis, a special technique must be used to anastomose it with the native pulmonary artery. If stenosis is present in the left and right pulmonary arteries, augmentation is performed using autologous pericardium or a cut-out ePTFE graft patch. If the difference between the calibers of the pulmonary artery and the conduit is large, turbulent blood flow can occur at the anastomosis and give rise to decreased blood flow energy and stenosis caused by intimal proliferation. Consequently, if stenosis is present near the pulmonary artery bifurcation, it should be augmented to the greatest extent possible. 17 We also reported that a conduit with a Z-score greater than or equal to 1.4 could increase the risk of anastomosis site stenosis. 15 The indication for pulmonary valve replacement owing to pulmonary regurgitation was RVEDVI greater than 150 mL/ m 2 , with no patients ''spontaneously'' remodeling to normal right ventricle volume if undergoing an operation when RVEDVI was greater than 170 mL/m 2 . 18 In this series, only 8 patients (2.6%) had RVEDVI greater than 150 mL/ m 2 , and only 3 of them (1.0%) had RVEDVI greater than 170 mL/m 2 ; however, all of them showed pulmonary regurgitation that was no greater than mild. That is, our conduit prevents pulmonary regurgitation and protects right ventricular function. With the growth of the adult population with congenital heart disease, pregnancy becomes an issue because of volume overload of the right ventricle in female patients. The conduit could help the right ventricle to tolerate the higher pressures during vaginal delivery. Therefore, these valves might be suitable for female patients who want to have children. In addition to preventing pulmonary regurgitation, fluid dynamically, because the flow rate is high on the greater curvature side, it is important to position one valve on that side to the greatest extent possible. The distal end of the greater curvature side is severed obliquely so that one valve is on the greater curvature side, and that side is slightly longer. 17 There were some cases in which the ePTFE conduits were compressed by the sternum. If the sinuses and valve are placed near the original pulmonary valve annulus, which is near the RVOT, there is a risk that the sinuses and the body of the conduit will be compressed and flattened by the sternum. Consequently, the ePTFE valve has to be positioned slightly to the pulmonary atresia side of the original annulus (Video 2). 17 From the histologic examination results, it can be inferred that the mineralization of the interstices of the leaflet, conduit, and suture associated with the leaflet attachment region may lead to compromised mobility of the leaflet, and the lymphohistiocytic inflammation might provoke mineralization. Because ePTFE has a microporous structure, which impedes cellular penetration, it might be difficult to prevent mineralization completely. However, calcification in the ePTFE material is very small compared with other bioprosthetic valves. Improvement and development of the ePTFE material itself to avoid mineralization are necessary to obtain better valvular function over the long term. The development of the ePTFE material is greatly anticipated. Therefore, to maintain good biocompatibility of the ePTFE and good valve function, we must determine the cause of degeneration in the ePTFE valved conduit. We give aspirin for 6 months and no warfarin after the operation. However, if the lymphohistiocytic inflammation might provoke mineralization, we should probably give aspirin longer.
Although further improvements such as prevention of calcification are needed to obtain better long-term outcomes, the use of ePTFE conduits with bulging sinuses and the fan-shaped ePTFE valves is associated with high freedom from reoperation and prevention of pulmonary insufficiency, which makes this a promising approach to RVOT reconstruction.
CONCLUSIONS
The fan-shaped valve with bulging sinuses on ePTFE conduits has beneficial effects on long-term valve function in RVOT reconstruction. These valves can provide excellent long-term outcomes even for infants and younger children, and they can offer a promising approach to RVOT reconstruction.
Webcast
You can watch a Webcast of this AATS meeting presentation by going to: https://aats.blob.core.windows.net/ media/17AM/2017-05-01/RM312/05-01-17_Room312_ 1400_Miyazaki.mp4.
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Dr Yamagishi receives personal fees from W.L. Gore & Associates, Inc, as a consultant. All other authors have nothing to disclose with regard to commercial support. the time, and I think it might be worth us taking a trip to Japan to learn how to make these conduits. For myself I certainly am now very interested in having a second reason to go to Japan.
Dr Takeshi Shinkawa (Little Rock, Ark). I was trained under Dr Yamagishi 15 years ago before I came to the US, and in Arkansas we are applying the exact same product with the Kyoto group, and we can reproduce a very good outcome. Regarding the use in the US, we get IRB approval from our institution. We asked the FDA if it is okay to deform the already commercial product and the FDA was okay. They said it fit into our scope of practice. As long as you make it and use it, it should be fine.
Dr Jaquiss. So the FDA, Bram Zuckerman is fond of saying they are not in the business of regulating the practice of medicine. So if, like Arkansas, you have someone on your campus who knows how to make these things, maybe we will hear a North American version of this.
Thank you very much. Dr Miyazaki. Thank you very much.
